Citation Impact
Citing Papers
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
2000 StandoutNobel
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
2002
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
2013
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography
1996
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
2012 StandoutNobel
Topoisomerase expression in cancer cell lines and clinical samples
1994
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines
2001
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
2005
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Marine natural products
1990 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
Reversal of Multidrug Resistance by 7-O-Benzoylpyripyropene A in Multidrug-Resistant Tumor Cells.
2000 StandoutNobel
Cremophor EL
2001 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
1997 Standout
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
2001
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
1996
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction
2005 Standout
Bioavailability enhancers of herbal origin: An overview
2013 Standout
Targeting multidrug resistance in cancer
2006 Standout
Synthesis and structure–activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein
2008
Expresssion of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells
1995
The Beclin 1 network regulates autophagy and apoptosis
2011 Standout
Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells
2012
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells
1995
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
2018 StandoutNobel
The Use of the MTT Assay to Study Drug Resistance in Fresh Tumour Samples
2003
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
2004
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
1988
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2003 Standout
Stem Cells and Cancer
2004 Standout
Role of Formulation Vehicles in Taxane Pharmacology
2001
Prenylated indole derivatives from fungi: structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis
2009 Standout
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells
2010
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Development of novel therapeutic strategies that target HIF-1
2006 StandoutNobel
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
2004
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
2001
Evaluation of HIF-1 inhibitors as anticancer agents
2007 StandoutNobel
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Oxygen homeostasis
2009 StandoutNobel
Haematopoietic Radioprotection by Cremophor EL: A Polyethoxylated Castor Oil
1995
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
N‐acyliminium intermediates in solid‐phase synthesis
2010 StandoutNobel
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
2003
Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.
2001
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
2001
Mechanisms of Cell Protection by Heme Oxygenase-1
2010 Standout
Tumour stem cells and drug resistance
2005 Standout
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Expression of the multidrug resistance associated protein and P- glycoprotein in doxorubicin-selected human myeloid leukemia cells
1994
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
2004
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
1996
HOXandNon‐HOXHomeobox Genes in Leukemic Hematopoiesis
2002
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
JAKS AND STATS: Biological Implications
1998 Standout
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein
2004
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Identifying marker genes in transcription profiling data using a mixture of feature relevance experts
2001
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38− progenitor cells from patients with acute myeloid leukemia
2001
Reversal of anticancer multidrug resistance by the ardeemins
1998
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
1998
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?
2015 Standout
Design and Syntheses of Permethyl Ningalin B Analogues: Potent Multidrug Resistance (MDR) Reversal Agents of Cancer Cells
2010
A multidrug resistance transporter from human MCF-7 breast cancer cells
1998 Standout
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
1996
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
2004
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
2001
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
2002 Standout
Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies
2014
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
2004 Standout
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Activity of Thymidine Kinase and of Polymerase α as Well as Activity and Gene Expression of Deoxycytidine Deaminase in Leukemic Blasts Are Correlated With Clinical Response in the Setting of Granulocyte-Macrophage Colony-Stimulating Factor–Based Priming Before and During TAD-9 Induction Therapy in Acute Myeloid Leukemia
1997
Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1
2007 StandoutNobel
Regulation of angiogenesis by hypoxia-inducible factor 1
2006 StandoutNobel
Works of DD Ross being referenced
Novel mechanisms of drug resistance in leukemia
2000
BP1, a new homeobox gene, is frequently expressed in acute leukemias
2000
Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia
1986
Metabolism of ara-C by blast cells from patients with ANLL
1986
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL
1994
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
1993
Metabolism of ara-C by blast cells from patients with ANLL
1986